FDA 483 OBSERVATION · #156 OF 1,923 MOST-CITED
Following/documenting laboratory controls
FDA cited this observation 197 times across 186 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
Drug CGMP requires laboratory controls to include scientifically sound specifications, standards, sampling plans, and test procedures that are established, documented, and followed; this citation means the lab either lacks such controls or does not follow and document them in practice.
Why FDA writes it — FDA cites this when laboratory work departs from its own written controls or leaves the deviations undocumented, because release decisions rest on lab data — if the controls are not followed and recorded, the data cannot be trusted to show the drug meets its specifications.
- Establish written laboratory controls — specifications, standards, sampling plans, and test procedures — that are scientifically sound.
- Follow the established procedures exactly and record any deviation with justification at the time it occurs.
- Document all laboratory data contemporaneously so results are attributable, complete, and reconstructable.
- Analysts adapt methods or sampling on the bench without revising or documenting against the approved procedure.
- Controls exist on paper but daily lab practice and its documentation drift away from them.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.6× the rate of the average FDA-cited firm (28.0% vs 7.8%), across 186 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Established laboratory control mechanisms are not followed.
Established test procedures are not documented at the time of performance.
Established specifications, standards, sampling plans, test procedures and laboratory control mechanisms are not followed and documented at the time of performance.
Established sampling plans are not followed.
Established laboratory control mechanisms are not followed.
Established test procedures and laboratory control mechanisms are not followed.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →